Accéder au contenu
Merck

The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview.

Journal of Alzheimer's disease : JAD (2016-03-12)
Angela L Jefferson, Katherine A Gifford, Lealani Mae Y Acosta, Susan P Bell, Manus J Donahue, L Taylor Davis, JoAnn Gottlieb, Deepak K Gupta, Timothy J Hohman, Elizabeth M Lane, David J Libon, Lisa A Mendes, Kevin Niswender, Kimberly R Pechman, Swati Rane, Frederick L Ruberg, Yan Ru Su, Henrik Zetterberg, Dandan Liu
RÉSUMÉ

Vascular health factors frequently co-occur with Alzheimer's disease (AD). A better understanding of how systemic vascular and cerebrovascular health intersects with clinical and pathological AD may inform prevention and treatment opportunities. To establish the Vanderbilt Memory & Aging Project, a case-control longitudinal study investigating vascular health and brain aging, and describe baseline methodology and participant characteristics. From September 2012 to November 2014, 335 participants age 60- 92 were enrolled, including 168 individuals with mild cognitive impairment (MCI, 73±8 years, 41% female) and 167 age-, sex-, and race-matched cognitively normal controls (NC, 72±7 years, 41% female). At baseline, participants completed a physical and frailty examination, fasting blood draw, neuropsychological assessment, echocardiogram, cardiac MRI, and brain MRI. A subset underwent 24-hour ambulatory blood pressure monitoring and lumbar puncture for cerebrospinal fluid (CSF) collection. As designed, participant groups were comparable for age (p = 0.31), sex (p = 0.95), and race (p = 0.65). MCI participants had greater Framingham Stroke Risk Profile scores (p = 0.008), systolic blood pressure values (p = 0.008), and history of left ventricular hypertrophy (p = 0.04) than NC participants. As expected, MCI participants performed worse on all neuropsychological measures (p-values < 0.001), were more likely to be APOEɛ4 carriers (p = 0.02), and had enhanced CSF biomarkers, including lower Aβ42 (p = 0.02), higher total tau (p = 0.004), and higher p-tau (p = 0.02) compared to NC participants. Diverse sources of baseline and longitudinal data will provide rich opportunities to investigate pathways linking vascular and cerebrovascular health, clinical and pathological AD, and neurodegeneration contributing to novel strategies to delay or prevent cognitive decline.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Millipore
MILLIPLEX® Human Circulating Cancer Biomarker Magnetic Bead Panel - Cancer Multiplex Assay, Circulating Cancer Biomarker Bead-Based Multiplex Assays using the Luminex technology enables the simultaneous analysis of multiple oncology biomarkers in various tumor types in human serum, plasma and cell culture samples.